Last reviewed · How we verify
NCT06054906
Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) for Resectable Locally Advanced Gastric Cancer
Phase 2 trial testing sintilimab+metronomic PLOF in Gastric Cancer in 50 participants. Currently enrolling.
30 June 2025
Quick facts
| Lead sponsor | Huashan Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 18 October 2023 |
| Primary completion | 30 June 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- sintilimab+metronomic PLOF — full drug profile →
Conditions studied
- Gastric Cancer — all drugs for Gastric Cancer →
Sponsor
Huashan Hospital
Who can join
18 and older, any sex, with Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate efficacy and safety of Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) in resectable locally advanced gastric cancer.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Current trends in sensitizing immune checkpoint inhibitors for cancer treatment.
Wei J, Li W, Zhang P, Guo F, et al · · 2024 · cited 82× · PMID 39725966 · DOI 10.1186/s12943-024-02179-5 -
Current Advances and Future Directions for Sensitizing Gastric Cancer to Immune Checkpoint Inhibitors.
Li W, Xu M, Cheng M, Wei J, et al · · 2025 · cited 7× · PMID 40686307 · DOI 10.1002/cam4.71065 -
Metronomic Chemotherapy in Elderly Patients.
Bandini A, Calabrò PF, Banchi M, Orlandi P, et al · · 2024 · cited 5× · PMID 38448722 · DOI 10.1007/s11912-024-01505-w
Verify or expand the search:
- PubMed search for NCT06054906
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastric Cancer
Currently open trials in the same condition.
- NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
- NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
- NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
Other Huashan Hospital trials
Trials by the same sponsor.
- NCT07469735 — Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma · NA · not yet recruiting
- NCT07364487 — This is an Open-Label Study to Assess the Safety and Efficacy of GC012F in Patients With Multiple Sclerosis · EARLY_PHASE1 · withdrawn
- NCT07369830 — The Impact of Probiotic Intervention on the Gut Microbiota and Bowel Function · NA · recruiting
- NCT07185373 — Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL · Phase 2, PHASE3 · not yet recruiting
- NCT07075029 — RSV in Acute Respiratory Infection Surveillance Among Community-Dwelling Elderly Aged ≥50 Years in China · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06054906 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Huashan Hospital
- Last refreshed: 30 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06054906.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing